Search

Grifols SA

Închisă

SectorFinanțe

10.16 1.04

Rezumat

Modificarea prețului

24h

Curent

Minim

10.025

Maxim

10.28

Indicatori cheie

By Trading Economics

Venit

-25M

73M

Vânzări

-282M

1.7B

P/E

Medie Sector

16.374

18.576

EPS

0.107

Marjă de profit

4.294

Angajați

25,000

EBITDA

78M

353M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-0.6% downside

Dividende

By Acuity

Următoarele câștiguri

3 nov. 2026

Data viitoare de dividende

12 aug. 2026

Următoarea dată ex-dividende

10 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

495M

6.6B

Deschiderea anterioară

9.12

Închiderea anterioară

10.16

Sentimentul știrilor

By Acuity

31%

69%

89 / 438 Clasament în Finance

Grifols SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 aug. 2026, 23:56 UTC

News

Diversified Healthcare Trust reported second-quarter FFO of $0.16, exceeding estimates. Revenue fell short at $365.39 million, contributing to a decline in after-market trading.

3 aug. 2026, 23:56 UTC

News

First Solar Inc reported second-quarter revenue of $1.06 billion and a net profit of $423 million. Shares are higher in after-hours trading.

3 aug. 2026, 23:52 UTC

Social Media
Correlated Moves
News

Microsoft shares are lower in after-market hours amid a class action lawsuit alleging misrepresentation of its Copilot products' performance and competitive position.

3 aug. 2026, 23:51 UTC

News

Marvell Technology plans a conference call for August 27, 2026, and an Investor Day on October 6, 2026. Shares are higher in after-market trading.

3 aug. 2026, 23:51 UTC

News

Rivian Automotive raises 2026 capital expenditure guidance to $1.7B-$1.8B, shares trade higher in after-market hours amid focus on cost management and production scaling.

3 aug. 2026, 23:51 UTC

News

JELD-WEN Holding Inc. reported second-quarter revenue of $817.8 million, exceeding forecasts. The company raised its full-year revenue guidance, boosting after-market trading sentiment.

3 aug. 2026, 23:51 UTC

Social Media
News

Palantir Technologies reported Q2 revenue of $1.94 billion, exceeding expectations. Shares rose sharply in after-market hours following strong earnings and raised guidance.

3 aug. 2026, 23:51 UTC

Social Media
News

Snap Inc. reported a narrower net loss of $163.96 million and revenue of $1.60 billion, exceeding expectations. Shares rose during after-market trading.

3 aug. 2026, 23:46 UTC

News

Novavax Inc is advancing in after-market trading as it shifts focus to licensing its Matrix-M adjuvant, attracting positive retail investor sentiment ahead of earnings.

3 aug. 2026, 23:46 UTC

News

CVS Health shares rose in after-market hours following a survey showing increased provider-payer trust scores and improved perceptions of digital tools in healthcare.

3 aug. 2026, 23:46 UTC

News

Alexandria Real Estate Equities reported a narrower net loss and FFO of $1.73, exceeding estimates. Shares traded higher in after-market hours.

3 aug. 2026, 23:46 UTC

Correlated Moves
News

Nova Ltd's after-market shares are higher, bolstered by strong analyst sentiment and a consensus price target of $603.38, reflecting a potential 54.4% return.

3 aug. 2026, 23:46 UTC

News

Realty Income Corp reported first-quarter revenue of nearly $1.55 billion, with adjusted funds from operations increasing to $1.06 billion. Shares were roughly flat after-market.

3 aug. 2026, 23:41 UTC

News

Teladoc Health remains effectively unchanged in after-market trading. Citigroup lowered its price target from $11.00 to $7.50 while maintaining a "neutral" rating.

3 aug. 2026, 23:41 UTC

News

Addus Homecare Corp reported Q2 revenue of $377.4 million and adjusted EPS of $1.73. Shares declined after the earnings announcement amid mixed market reactions.

3 aug. 2026, 23:41 UTC

News

Hims & Hers Health shares are higher in after-market trading, following positive growth insights despite facing a lawsuit from the Federal Trade Commission.

3 aug. 2026, 23:41 UTC

Correlated Moves
News

DA Davidson raised its price target for First Business Financial Services to $80, contributing to higher shares in after-market trading.

3 aug. 2026, 23:41 UTC

News

Karyopharm Therapeutics shares are lower in after-market hours following the grant of restricted stock units to a new employee, raising potential dilution concerns.

3 aug. 2026, 23:41 UTC

News

Andersons Inc. shares rise in after-market trading following strong Q2 results, with adjusted net income of $73.6 million exceeding expectations.

3 aug. 2026, 23:41 UTC

Social Media
News

BWX Technologies shares are lower in after-market hours following a revenue miss of $901.6 million and a divestiture of its medical business to Nordic Capital.

3 aug. 2026, 23:41 UTC

Social Media
News

Williams Companies announced an agreement to acquire Momentum Midstream for up to $5.5 billion, boosting its natural gas infrastructure and supporting Gulf Coast demand.

3 aug. 2026, 23:41 UTC

News

Ichor Holdings shares lower in after-market trading following a revenue miss of $294.8 million and EPS of $0.03, below expectations.

3 aug. 2026, 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

3 aug. 2026, 23:31 UTC

News

Ameresco shares rose in after-market trading following strong Q2 results, with revenues of $515.5 million exceeding expectations and a record $1.8 billion in new project awards.

3 aug. 2026, 23:31 UTC

News

UBS raised its price target on Colgate-Palmolive Co to $109, maintaining a Buy rating. Shares are trading higher in after-market hours.

3 aug. 2026, 23:31 UTC

Social Media
News

Grab Holdings reported strong Q2 results, with earnings per share of 6 cents and revenue of $997 million. Shares are higher in after-market hours.

3 aug. 2026, 23:31 UTC

News

Ultra Clean Holdings reported Q2 net income of $11.9 million and revenue of $644.9 million, raising its Q3 outlook to between $700 million and $750 million.

3 aug. 2026, 23:26 UTC

Social Media
News

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, exceeding estimates. The company raised its full-year guidance to between $13.1 billion and $13.2 billion.

3 aug. 2026, 23:21 UTC

News

Banner Corp announces a buyback of up to 1.7 million shares, aiming to enhance long-term shareholder value. Shares are higher in after-market trading.

3 aug. 2026, 23:21 UTC

News

Inspire Medical Systems reported Q2 adjusted EPS of $0.14, exceeding expectations. The company raised its full-year EPS guidance to between $1.05 and $1.45.

Comparație

Modificare preț

Grifols SA Așteptări

Obiectiv de preț

By TipRanks

-0.6% jos

Prognoză pe 12 luni

Medie 10 EUR  -0.6%

Maxim 10 EUR

Minim 10 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGrifols SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

1 ratings

0

Cumpărare

1

Păstrare

0

Vânzare

Sentiment

By Acuity

89 / 438 Clasament în Finanțe

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
help-icon Live chat